Safety and intestinal microbiota modulation by the exopolysaccharide-producing strains Bifidobacterium animalis IPLA R1 and Bifidobacterium longum IPLA E44 orally administered to Wistar rats by Salazar, Nuria et al.
 1
Title: Safety and intestinal microbiota modulation by the exopolysaccharide-producing strains 1 
Bifidobacterium animalis IPLA R1 and Bifidobacterium longum IPLA E44 orally 2 
administered to Wistar rats.  3 
 4 
Authors: Nuria Salazar1, Ana Binetti1,4, Miguel Gueimonde1, Ana Alonso2, Pablo Garrido2, 5 
Carmen González del Rey3, Celestino González2, Patricia Ruas-Madiedo1 and Clara G. de los 6 
Reyes-Gavilán1,* 7 
 8 
Addresses: 9 
1: Department of Microbiology and Biochemistry of Dairy Products. Instituto de Productos Lácteos de 10 
Asturias – Consejo Superior de Investigaciones Científicas (IPLA-CSIC). Carretera de Infiesto s/n, 11 
33300 Villaviciosa, Asturias, Spain. 12 
2: Department of Functional Biology, Physiology Area. University of Oviedo. C/ Julián Clavería s/n, 13 
33006 Oviedo, Asturias, Spain. 14 
3 Pathology Department. San Agustin Hospital, Avilés, Spain 15 
4: Instituto de Lactología Industrial (UNL - CONICET), Faculty of Chemical Engineering, 16 
Universidad Nacional del Litoral, 1º de Mayo 3250, 3000, Santa Fe, Argentina.  17 
 18 
Short title:  19 
Bifidobacterium animalis and Bifidobacterium longum administered to Wistar rats 20 
Key words:  21 
Bifidobacterium, Wistar rats, intestinal microbiota, modulation, exopolysaccharide 22 
* Corresponding author: Instituto de Productos Lácteos de Asturias – Consejo Superior de 23 
Investigaciones Científicas (IPLA-CSIC). Carretera de Infiesto s/n, 33300 Villaviciosa, 24 
Asturias, Spain. 25 
Tel.: +34 985892131; Fax: +34 985892233; E-mail: greyes_gavilan@ipla.csic.es  26 
27 
 2
ABSTRACT 28 
Bifidobacterium animalis subsp. lactis IPLA R1 and Bifidobacterium longum IPLA 29 
E44 strains were tested in vivo for their safety and ability to modulate the intestinal 30 
microbiota. Chemically simulated gastrointestinal digestion showed considerably lower 31 
survival of E44 than R1 strain, the first microorganism also being more sensitive to 32 
refrigerated storage in 10%- skimmed milk at 4ºC. Harmful glycosidic activities were absent, 33 
or at low levels, in the strains R1 and E44. Both strains were sensitive to most antibiotics and 34 
resistant to aminoglycosides, a common feature in bifidobacteria. Similarly to several other 35 
bifidobacteria strains, B. animalis subsp. lactis IPLA R1 displayed a moderate resistance 36 
against tetracycline which correlated with the presence of tet(W) gene in its genome. The 37 
general parameters indicating well-being status, as well as translocation to different organs 38 
and histological examination of the gut tissues, revealed no changes induced by the 39 
administration of bifidobacteria.  12 week-old male Wistar rats were distributed into three 40 
groups, eight rats in each. Two groups were administered daily over 108 cfu of the 41 
corresponding strain suspended in 10%- skimmed milk for 24 days, whereas rats in the 42 
placebo group received skimmed milk without microorganisms added. The microbiota and 43 
short chain fatty acids (SCFA) were monitored in faeces at different time points during 44 
treatment and in caecum-content at the end of the assay. Quantitative PCR (qPCR) showed 45 
that faecal and caecal Bifidobacterium levels were higher in bifidobacteria-fed rats than in the 46 
placebo rats at the end of the intervention, whereas total anaerobic-plate counts did not show 47 
significant differences. Quantification of B. animalis and B. longum by qPCR showed that, 48 
independent of the microorganism administered, treatment with bifidobacteria resulted in 49 
higher levels of B. animalis in the caecum. PCR-DGGE analysis of microbial populations 50 
revealed a higher diversity of bands in caecum-content of rats fed B. animalis IPLA R1 than 51 
in the placebo group and rats fed B. longum IPLA E44. Remarkably, although no variations in 52 
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the proportion of acetate, propionate and butyrate were found, at the end of the assay the total 53 
SCFA concentration in the faeces of rats fed bifidobacteria was significantly higher and those 54 
in caecum-content significantly lower, than that of the placebo group. This suggests a 55 
displacement of the SCFA production to parts of the colon beyond the caecum in rats 56 
receiving bifidobacteria. Therefore, the oral administration of B. animalis IPLA R1 and B. 57 
longum E44 can be considered safe, these microorganisms having the ability to modulate the 58 
intestinal microbiota of rats by influencing SCFA and the bifidobacterial population levels.  59 
 60 
 61 
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INTRODUCTION 62 
The distal gastrointestinal tract (GIT) works as an anaerobic bioreactor, composed of 63 
relatively few microbial phyla with high diversity at species/strain level, and it mediates 64 
important host physiological functions as well as chemical transformations of indigestible 65 
components of the diet (Bäckhed et al., 2005). This symbiotic relationship between intestinal 66 
microbiota and host is crucial for maintaining a health status and several intervention 67 
strategies have been developed to keep this homeostasis. The FAO/WHO defined probiotics 68 
as “live microorganisms which when administered in adequate amounts confer a health 69 
benefit on the host”. A FAO /WHO expert consultation group has proposed a guideline in 70 
order to assess the health properties and safety considerations of probiotics intended for 71 
human food applications. Several rational criteria, based on in vitro and in vivo evidences, are 72 
currently recommended for the selection of putative probiotic strains before assessing their 73 
efficacy in human intervention studies (FAO/WHO 2006). 74 
Lactobacillus and Bifidobacterium are the most frequently used probiotics for human 75 
consumption, and due to their long history of safe use, some species have the “Qualified 76 
Presumption of Safety” (QPS) status (EFSA, 2007). In recent years, our research group has 77 
been working with bifidobacteria strains isolated from human intestinal microbiota which are 78 
able to produce exopolysaccharides (EPS) (Ruas-Madiedo et al., 2007). Bacterial EPS have 79 
been claimed to play an important role in the putative probiotic effect of some producing 80 
strains (Ruas-Madiedo et al., 2008). The EPS synthesised by bifidobacteria are able to modify 81 
the adhesion of probiotics and entero-pathogens to human mucus (Ruas-Madiedo et al., 82 
2006). It has also been suggested that bacterial EPS could play a protective role for the 83 
producing strain under adverse environmental conditions (Ruas-Madiedo et al., 2008). In 84 
addition, EPS from bifidobacteria can be used as fermentable substrates by the human 85 
intestinal microbiota (Salazar et al., 2008). Namely, we have recently shown that the EPS 86 
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produced by the strains Bifidobacterium animalis subsp. lactis IPLA R1 and Bifidobacterium 87 
longum subsp. longum IPLA E44 were able to modify levels of microbial intestinal 88 
populations and to promote shifts in the production of short chain fatty acids (SCFA) when 89 
tested in a pH-controlled human faecal model that simulates the distal part of the gut (Salazar 90 
et al., 2009). A suitable approach to modulate the intestinal microbiota, and thus to exert a 91 
health benefit, could be the use of the EPS-producing bifidobacteria. However, before 92 
embarking on long and expensive human intervention studies it is important to have good in 93 
vivo evidence, as well as to ascertain the safety of such strains. In this way, the aim of the 94 
present study was to determine the safety of strains B. animalis subsp. lactis IPLA R1 and B. 95 
longum subsp. longum IPLA E44 by means of several in vitro and in vivo tests, to ascertain 96 
their ability to survive the upper GIT challenge and to assess the capability of these strains to 97 
modulate the intestinal microbiota in an in vivo animal model. 98 
 99 
MATERIALS AND METHODS 100 
Bacterial strains and culture conditions 101 
 Two EPS-producing strains were used in this study: B. animalis subsp. lactis IPLA R1 102 
and B. longum subsp. longum IPLA E44, both held at the IPLA culture collection [GenBank 103 
accession numbers of their partial 16S rRNA gene sequence: EU430035 (Salazar et al., 2008) 104 
and GU586289 (this article), respectively]. Strains from frozen stocks were re-activated 105 
overnight at 37ºC in MRSC [MRS broth (Biokar Diagnostic, Beauvais, France) supplemented 106 
with 0.25% (w/v) L-cysteine (Sigma Chemical Co., St. Louis, MO, USA)] in an anaerobic 107 
chamber Mac500 (Don Whitley Scientific, West Yorkshire, UK) under 80% N2 (v/v), 10% 108 
(v/v) CO2 and 10% (v/v) H2 atmosphere.  109 
Suspensions of each strain were separately prepared in milk to be administered to 110 
experimental animals. Cultures grown overnight were used to inoculate (2% w/v) fresh 111 
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MRSC broth which was incubated for 24 h under the conditions previously indicated. 112 
Afterwards, cultures were washed twice with sterile PBS solution (8.0 g/L NaCl, 0.2 g/L KCl, 113 
1.15 g/L Na2HPO4 and 0.2 g/L KH2PO4; pH 7.3) and resuspended in sterile 10%-reconstituted 114 
skimmed milk (Difco™, Becton Dickinson, MD, USA) at a concentration of about 1x1010 115 
cfu/mL. Two milk-bacterial suspension batches for each strain were prepared weekly and 116 
stored during a maximum of  4 days at 4ºC until administration to animals. To test the 117 
viability of the strains in the milk-bacterial suspensions under cold storage, serial dilutions in 118 
Ringer’s solution (Merck, Darmstadt, Germany) were made and deep plated on agar-MRSC. 119 
Plates were incubated under anaerobic conditions for 72 h to determine the bifidobacteria 120 
counts (cfu/mL). The identity of the strains was tested in some batches by partially 121 
sequencing the 16S rRNA gene using Y1-Y2 primers (Salazar et al., 2009). 122 
 123 
Simulated gastrointestinal transit of bifidobacteria  124 
The survival of the two bifidobacteria strains to the GIT transit was studied in an in 125 
vitro model that chemically simulates physiological conditions, which had been modified 126 
from those previously described (Fernández et al., 2003). The following preparations were 127 
used: (i) gastric juice (GJ) containing 125 mmol/L NaCl, 7 mmol/L KCl, 45 mmol/L 128 
NaHCO3, and 3 g/L pepsin (Sigma), pH 2.0 adjusted with HCl, (ii) duodenal juice (DJ) 129 
containing  bovine 1% (w/v) bile (Sigma) pH 8.0 adjusted with 10 N NaOH, and (iii) 130 
intestinal juice (IJ) containing 0.3% (w/v) bovine bile, 0.1%  (w/v) pancreatin (Sigma), pH 131 
8.0 adjusted with 10 N NaOH. To simulate the GIT transit, the bacterial suspensions were 132 
sequentially submitted to the GJ, DJ and IJ conditions as follows. Cells from 24 h MRSC-133 
grown cultures were harvested by centrifugation (10,000 g, 15 min, 5ºC), washed twice with 134 
0.85% (w/v) NaCl and concentrated 10 fold. For each strain, 100 μL of the concentrated 135 
suspensions were centrifuged and resuspended either in 1 mL of GJ or in 1 mL of GJ 136 
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containing 10% skimmed milk, which increased the pH of the bacterial suspension to about 137 
4.0. Bacterial suspensions were then incubated for 90 min at 37ºC with mild stirring (200 138 
rpm). Afterwards, cells were harvested (10,000 g, 15 min), resuspended in DJ and incubated 139 
anaerobically for 10 min at 37ºC. After this step, cells were harvested again, resuspended in 140 
the IJ and incubated for 120 min at 37ºC in anaerobic conditions. Initially, and after each step, 141 
samples were taken to determine bacterial counts (cfu/mL) as previously indicated. 142 
Additionally, at the end of the simulation of GIT transit bacterial suspensions were collected 143 
and dyed with the Live/Dead® BacLight bacterial viability kit (Molecular Probes, Invitrogen, 144 
Merck) following the manufacturer’s instructions. Fluorescence was measured in a Cary 145 
Eclipse fluorescence spectrophotometer (Varian Ibérica S.A., Madrid, Spain). The ratio 146 
between live (cultivable and non-cultivable, green colour) and dead (red colour) bacteria was 147 
used to calculate the percentage of survival. 148 
 149 
Enzymatic activities and antibiotic resistance of bifidobacteria 150 
 Several enzymatic activities were determined using the semi-quantitative method Api-151 
ZYM (BioMérieux, Montalieu-Vercieu, France) following the manufacturer´s instructions. 152 
The minimum inhibitory concentration (MIC) of eight antibiotics (gentamicin, kanamycin, 153 
streptomycin, neomycin, tetracycline, erythromycin, clindamycin and chloramphenicol) was 154 
determined against the strains, previously grown under conditions described by Klare et al. 155 
(2005), using the VetMicTM Lact-I microdilution test (SVA, Uppsala, Sweden) following the 156 
manufacturer´s specifications. High antibiotic resistance levels were further corroborated by 157 
E-test strips (AB Biodisk, Solna, Sweden), as indicated by Ammor et al. (2008). Finally, the 158 
presence of tetracycline resistance genes encoding ribosomal protection proteins was 159 
determined  by PCR using two pairs of degenerated primers, DI-DII and Tet1-Tet2, and 160 
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primers TetWF-Tet2 specific for the gene tet(W) according to the procedure described by 161 
Flórez et al. (2006).  162 
 163 
Animal model and experimental design 164 
The study was approved by the Animal Experimentation Ethical Committee of the 165 
Oviedo University, and subsequent handling strictly followed the European Communities 166 
Council Directive of November 24, 1986 (86/609/EEC). 12 week-old male Wistar rats (300-167 
350 g body weight) were obtained from the Oviedo University Bioterio Facility. Animals 168 
were fed ad libitum a commercial diet (PanlabAO4, Panlab S.L., Barcelona, Spain) and were 169 
kept at 23-25ºC and 12/12 h light-dark cycle, each rat housed in an individual cage. Animals 170 
were divided into three groups (n = 8 rats per group): i) placebo group, ii) B1 group (fed B. 171 
animalis subsp. lactis IPLA R1) and iii) B2 group (fed B. longum subsp. longum IPLA E44).. 172 
The placebo group received 100 μL of sterile skimmed milk daily, and each rat of the B1 and 173 
B2 groups received a dose of 109 cfu per day of the corresponding milk-bifidobacteria 174 
suspension in a volume of 100 μL. Placebo and milk-bifidobacteria suspensions were orally 175 
administered for 24 days by means of an intragastric cannula under light halothane 176 
anaesthesia. Each bacterial preparation was used for feeding animals during four consecutive 177 
days. Before starting the intervention study, each rat was maintained in the cage for 3 days 178 
and afterwards they were monitored daily for weight changes. Additionally, a control group 179 
of 8 rats was maintained for 3 days in individual cages and then killed to obtain caecal content 180 
at day 0 of intervention. Faeces were collected at 0 (first day of intervention), 4, 11, 18 and 24 181 
days. After 24 days of treatment, the animals were anaesthetized with halothane and, as soon 182 
as anaesthesia was assured by loss of pedal and corneal reflexes, they were killed by 183 
exsanguination. The liver, spleen, mesenteric lymphoid nodes, small intestine, caecum and 184 
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rest of the large intestine were aseptically excised. The caecum-content was also collected. All 185 
samples were kept at 4ºC until processing for analyses within the next few hours. 186 
 187 
Histopathological evaluation 188 
Samples of the whole intestinal tract were removed, and segments of approximately 2 189 
cm were taken from the duodenum, the midpoint between the bile duct entry and Meckel’s 190 
diverticulum (jejunum), proximal caecum and rectum. The small intestine and large intestine 191 
samples were fixed by immersion in 10% buffered formalin. The samples were then washed 192 
overnight with tap water and were dehydrated through a graded series of ethanol. They were 193 
incubated in xylene and then embedded in paraffin. Serial sections (5 μm) were taken from all 194 
groups and collected onto gelatin-coated slides. Sections were deparaffinized at 60°C 195 
overnight, immersed in xylene and rehydrated through a graded series of ethanol. All 196 
histological studies were performed on 5 μm sections, stained by haematoxylin and eosin 197 
(HE), and examined by light microscope by an experienced pathologist. 198 
 199 
Organs, faeces and caecum-content cultivation 200 
 The liver, spleen and mesenteric lymphoid nodes as well as the faeces and caecum-201 
content were cultivated immediately after collection. Samples were diluted 1/10 in sterile PBS 202 
solution and homogenised for 4 min in a LabBlender 400 stomacher (Seward Medical, 203 
London, UK). Serial dilutions were made in Ringer’s solution and deep plated into GAM 204 
broth (Nissui Pharmaceuticals, Japan) supplemented with 0.25% (w/v) L-cysteine (Sigma) for 205 
total cultivable anaerobes counting.  206 
 207 
DNA isolation from faeces and caecum-content 208 
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DNA was extracted from the homogenised faeces and caecum-content using the 209 
QIAamp® DNA stool kit (Qiagen GmbH, Hilden, Germany) following the manufacturer’s 210 
specifications. For this purpose, an aliquot of 1 mL was centrifuged (10,000 g, 15 min, 4ºC) 211 
and the pellet was washed twice with PBS and resuspended in the first reagent of the kit. 212 
 213 
Quantitative determination of bifidobacteria in the caecum-content and faeces 214 
The quantification of the Bifidobacterium genus and the species B. animalis and B. 215 
longum was carried out by qPCR. Previously described primers were used for the genus 216 
(Gueimonde et al., 2004b), B. animalis (Lahtinen et al., 2005) and B. longum (Gueimonde et 217 
al., 2006). All reactions were performed in MicroAmp optical plates sealed with MicroAmp 218 
optical caps (Applied Biosystems, Foster City, CA, USA) using a 7500 Fast Real Time PCR 219 
system (Applied Biosystem) with Sybr green PCR master mix (Applied Biosystems) under 220 
conditions previously reported (Salazar et al., 2008). 221 
 222 
Qualitative determination of the total microbiota in caecum-content and faeces  223 
 The evolution of the microbiota in faeces during the intervention study and the 224 
microbiota fingerprint of the caecum-content after the administration period (24 days) were 225 
determined by PCR-DGGE. Previously described universal primers  (Nübel et al., 1996) were 226 
used. The reaction mixture (50 μL) contained 0.25 μmol/L of each primer, 200 μmol/L of 227 
each deoxynucleoside triphosphate (Amersham Bioscience, Uppsala Sweden), 2.5 U of Taq 228 
polymerase (Eppendorf, Hamburg, Germany) and 3 μL of DNA from faeces or caecum 229 
content. The amplification program was: 94ºC for 5 min, 35 cycles of 94ºC for 30 s, 58ºC for 230 
20 s, 68ºC for 40 s and the final elongation step of 68ºC for 7 min. The PCR reaction was 231 
carried out in an iCycler (BioRad Laboratories, Hercules, CA, USA) apparatus. The PCR 232 
products were separated by DGGE in a DCode system (BioRad Laboratories) as described by 233 
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Salazar and co-workers (2008). Bands were randomly selected to cover variability among rats 234 
and study groups. Bands were excised from the gel and used to perform a secondary PCR 235 
reaction with the same primers without the GC clamp. After purification, the amplified PCR 236 
products were sequenced and partially identified by comparison with data held in the 237 
GenBank database (Salazar el al., 2008).  238 
 239 
Determination of the SCFA in faeces and caecum-content 240 
The analysis of SCFA was carried out by CG-MS as follows. Supernatants from 1 mL 241 
of the homogenized faeces and caecum-content samples were obtained by centrifugation 242 
(10,000 g, 30 min, 4ºC) and filtration (0.45 μm). A chromatographic system composed of a 243 
6890N GC (Agilent Technologies Inc., Pal Alto, CA, USA) connected with an ion flame 244 
detector and a mass spectrometry 5973N detector (Agilent) was used for quantification as 245 
described previously (Salazar et al., 2008).  246 
 247 
Statistical analysis 248 
Results were analysed using the SPSS v.15 (SPSS Inc. Chicago, USA) software by 249 
means of independent one-way ANOVA tests in each sampling point. The differences among 250 
the three rat groups were assessed by means of the LSD (least significant difference) mean 251 
comparison test (p<0.05). To analyse the PCR-DGGE diversity (number of bands), the non-252 
parametric Mann-Whitney test for independent samples was used for pair comparisons 253 
between treatment groups. 254 
 255 
RESULTS 256 
Viability of bifdobacteria under refrigerated storage and simulated GIT transit 257 
conditions 258 
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The viability of the bacterial suspensions in milk stored at 4ºC was tested daily for 4 259 
days. The reduction of microbial counts after this time was 0.15±0.14 log units for B. 260 
animalis IPLA R1 and 1.01±0.27 log units for B. longum IPLA E44. The strain R1 remained 261 
without noticeable viability loss during cold storage, whereas the viability of E44 rapidly 262 
declined after 3 days. Thus, the daily consumption of viable bacteria in rats fed both strains 263 
was close to 109 cfu per day, except for the 4th day of administration of each E44 preparation 264 
(once a week) from which animals received around 108 cfu due to the loss of viability of this 265 
microorganism during storage. 266 
Survival to the chemically simulated GIT transit of bifidobacteria is depicted in Figure 267 
1. Challenge to GJ pH 3.0 caused similar reduction of counts in both strains (1.15 and 1.54 268 
log units for R1 and E44, respectively). However, in GJ pH 2.0 B. longum IPLA E44 269 
population underwent a drastic drop (5.1 log units) whereas B. animalis IPLA R1 showed 270 
similar counts decrease (1.22 log units) as at pH 3.0. This indicates a lower tolerance of B. 271 
longum than B. animalis to the acidic conditions. The presence of milk in the GJ pH 2.0 272 
increased the pH of the mixture to about 4.0 and counteracted the negative effect of the acid 273 
on the strain E44, counts being reduced by only 0.36 log units in these conditions. Regarding 274 
the DJ challenge, the strain E44 was also more sensitive to the adverse effects of bile salts 275 
(counts reduction of 5.73 log units) than strain R1. The presence of milk in the initial bacterial 276 
suspension also protected strain E44 against the subsequent negative effect of bile, the 277 
reduction of counts being much lower than without milk. At the end of the sequentially 278 
simulated GIT transit, counts of R1 were reduced by about 1.6 log units in all conditions 279 
tested, whereas the reduction of the populations of E44 was between 3.5 log units and 5.6 log 280 
units, depending on the initial GJ conditions. When using the Live/Dead® BacLight bacterial 281 
viability kit after sequential GIT challenge, the number of viable cells was under the detection 282 
limit for B. longum IPLA E44 (data not shown). For strain R1, viable cells were not found at 283 
 13
initial GJ challenge at pH 2.0, however, the percentage of survival was 57.1±10.1 and 284 
72.6±3.1 for initial GJ pH 3.0 and pH 2.0+milk, respectively (p<0.05). These results 285 
corroborated the higher resistance to the GIT conditions of strain R1 with respect to strain 286 
E44 and the protective effect exerted by milk. 287 
 288 
In vitro and in vivo safety of bifidobacteria strains  289 
The enzymatic activities and antibiotic MIC values determined for B. animalis IPLA 290 
R1 and B. longum IPLA E44 (Supplementary Material 1). Both strains displayed moderate 291 
phosphatase, esterase-lipase and peptidase activities, with the exception of the high activity of 292 
leucine arylamidase. The proteolytic activities trypsin and α-chymotrypsin were not detected. 293 
The most active glycolytic enzymes were β-galactosidase and α-glucosidase, whereas α-294 
galactosidase, β-glucosidase and N-acetyl-β-glucosaminidase displayed only moderate 295 
activity and β-glucuronidase, α-manosidase and α-fucosidase were not detected. Both strains 296 
displayed high MIC values for some aminoglycosides (gentamycin, kanamycin, and 297 
streptomycin). In addition, tetracycline resistance was found in strain R1(16 µg/mL) but not 298 
in strain E44.  PCR amplification of genes encoding ribosomal protection proteins and the 299 
tet(W) gene which confer tetracycline resistance were also positive for R1 but not for E44 300 
strains.  301 
With respect to the in vivo experiments of safety, no animal death, abnormal variations 302 
in food or water intake, or unexpected behaviour were observed for any animal group during 303 
the bifidobacteria intake. In addition, no significant variations (p > 0.05) in the animal weight 304 
were noticed among the three groups of rats during the treatment [381.0±8.2, 377.0±4.3 and 305 
373.8±7.6 g, for animals fed placebo, B. animalis IPLA R1 (B1 group) and B. longum IPLA 306 
E44 (B2 group) respectively, at 24 days of treatment]. The total anaerobe counts obtained 307 
from liver, spleen and mesenteric nodes in the groups of rats fed placebo, R1 and E44 strains 308 
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(Supplementary Material 2) did not differ significantly (p > 0.05) among them for any tissue 309 
analyzed, indicating that the oral administration of these microorganisms did not promote 310 
bacterial translocation.   311 
 312 
Histopathological evaluation 313 
No pathological changes were observed macroscopically and microscopically, in 314 
either the small intestine or large intestine, for any of the rats analyzed from the control and 315 
experimental groups at 0 and 24 days of treatment. No histopathological changes were 316 
observed in villi and crypts of small intestine or in mucose of the large intestine in the placebo 317 
group and in bifidobacteria-fed rats (group B1 and group B2 respectively) (Figure 2). 318 
 319 
Quantification of bifidobacteria in the intestinal microbiota of rats 320 
The quantification of total bifidobacteria and the levels of species B. animalis and B. 321 
longum in faecal and caecum-content of rats were achieved by qPCR (Figure 3). The 322 
evolution of total bifidobacteria in faecal samples at different sampling points during 323 
treatment (Figure 3a) showed a similar performance; after an initial increase of about 0.5 log 324 
units on day 4, which was probably related to changes in the diet caused by the intake of milk, 325 
the counts returned to their initial levels (7.80±0.15 log cfu/g) at the next sampling point (12 326 
days). No statistical differences (p > 0.05) were found among the three groups of rats at 4, 11 327 
and 18 days of feeding whereas Bifidobacterium counts were significantly higher (p < 0.05) 328 
after 24 days in faeces or rats fed either R1 or E44 strains (7.79±0.15 and 7.80±0.19 log cfu/g, 329 
respectively) than in faeces of in the placebo group (7.55±0.18 log cfu/g). Regarding the 330 
results obtained for the caecum content  (Figure 3b), total counts of Bifidobacterium genus 331 
and counts of B. animalis species in the placebo group did not show any significant change at 332 
the end of the treatment with respect to the initial values (day 0), whereas counts of B. longum 333 
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were reduced by 1 log unit. In spite of that, with the only exception of B. longum counts in B1 334 
group, levels of total bifidobacteria, B. animalis and B. longum after 24 days of probiotic 335 
administration  were significantly (p< 0.01) higher in caecum of rats fed bifidobacteria, than 336 
in rats fed the placebo. Independent of the species orally administered, treatment with 337 
bifidobacteria promoted higher levels of the species B. animalis with respect to the placebo 338 
group whereas only the administration of the strain B. longum IPLA E44 resulted in 339 
significantly (p < 0.05) higher levels of B. longum. Finally, the counts of total bifidobacteria 340 
were in the same order of magnitude (from 7.5 to 8.0 log units, depending on the group of 341 
rats) in faecal and in caecum-content samples. 342 
 343 
Population dynamics of the rat intestinal microbiota 344 
The evolution of total cultivable anaerobes in faecal samples remained without 345 
noticeable modifications at the four sampling points taken during the treatment period (data 346 
not shown). No significant differences (p > 0.05) were detected in faeces and caecum-content 347 
among the three groups of rats and the levels found after 24 days of intervention were similar 348 
in both types of samples (between 9.03±0.28, and 8.79±0.39 log cfu/g in faeces and between 349 
8.57±0.25, and 8.30±0.44 cfu/g in caecum-content). These results indicate that the oral intake 350 
of bifidobacteria didn’t have a noticeable effect in the levels of the total cultivable intestinal 351 
anaerobic population. 352 
Figure 4 shows the PCR-DGGE fingerprint of the caecal microbial community of four 353 
rats per group, and Table 3 shows the identification at species level of some selected bands. A 354 
high variability intra- and inter-groups was detected from the patterns of bands, each rat 355 
presenting a specific microbiota fingerprint. As a consequence, a pattern related to the oral 356 
administration of the two bifidobacterial strains could not be identified. However, the 357 
microbial diversity measured as the number of bands (Figure 4b) of the caecum-microbiota, 358 
 16
was significantly higher (p < 0.001) in the group of rats fed B. animalis IPLA R1 (B1 group) 359 
than in rats fed placebo or B. longum IPLA E44 strain (B2 group). Most of the 21- selected 360 
bands identified (Table 1) corresponded to microorganisms belonging to clostridial XIVa and 361 
bands of microorganisms included in clostridial clusters IV and XI were also identified. 362 
Similar results were obtained for faecal samples (data no shown) in which, only 3 out of 24 363 
bands identified were lactobacilli from Lactobacillus johnsonii (97% similarity) Lactobacillus 364 
murinus / Lactobacillus animalis (100% similarity) and Lactobacillus reuteri (98% similarity) 365 
species. In caecum-samples, band 2 (Ruminococcus gnavus) was present in all rats analysed 366 
and band 19 (Clostridium citroniae / Clostridium clostridiiformes) appeared in at least one rat 367 
from each group. It is worth mentioning that species considered as butyrate-producers were 368 
found in the three groups of rats. This is the case of Butyrivibrio crossotus (bands 1 and 3), 369 
Coprococcus eutactus (band 7), Clostridium sporosphaeroides (bands 8 and 12), 370 
Coprococcus catus (band 13) and Eubacterium halii (bands 17 and 21).  371 
 372 
Metabolic activity of the intestinal microbiota of rats 373 
The metabolic activity of the intestinal microbiota was determined by measuring the 374 
SCFA concentration in faeces and caecum-content samples. The concentration of total and 375 
major SCFA (acetate, propionate and butyrate) detected in faeces, increased during the 376 
treatment in the three groups of rats with respect to the initial levels (rats at 0 days) (Table 2), 377 
although no variation in the proportions of major SCFA was found. The most abundant SCFA 378 
in faeces was acetate (around 70%) followed by butyrate and propionate, present in similar 379 
proportions (around 17% and 13%, respectively). Regarding the comparison among the three 380 
groups of rats, in all sampling points, with the exception of day 18 for B1 group, the 381 
concentration of total SCFA was significantly (p < 0.01) higher in animals fed bifidobacteria 382 
than in the placebo group. However, the proportions of the three major acids remained similar 383 
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in the three treatment-groups with the exception of results obtained at 4 days of intervention. 384 
At this time, a significant (p < 0.01) decrease of acetate and a concomitant increase of 385 
butyrate were obtained in rats fed B. longum IPLA E44. A similar tendency was observed on 386 
day 11 in rats fed B. animalis IPLA R1. Thus, it seems that the increase of butyrate is 387 
correlated with a decrease in acetate levels in the faecal samples at intermediate times during 388 
the oral administration of bifidobacteria. 389 
The SCFA profile obtained in caecum-content samples (Table 2) was remarkably 390 
different from that of faeces. The acetate was also the most abundant SCFA (around 44%), 391 
but its proportion was considerably lower than in faecal samples which was in favour of a 392 
higher butyrate proportion in caecum than in faeces (around 37%). The propionate remained 393 
as the least abundant component (around 18%). Contrary to that found in faeces, comparison 394 
among the three groups of rats showed that total and major SCFA concentrations were 395 
significantly lower (p< 0.001) in  rats fed bifidobacteria strains than in the placebo group.  396 
 397 
DISCUSSION 398 
 Several in vitro and in vivo tests have been proposed by a FAO/WHO experts group 399 
(2006) in order to gain insight on strain properties and mechanisms of probiotic effect, as well 400 
as on some safety considerations. For bifidobacteria that will be ingested orally included in a 401 
probiotic food, survival during the storage of the product, and through the GIT transit, is a 402 
desirable property. Suspension in milk at 4ºC for 4 days caused greater viability loses in B. 403 
longum IPLA E44 than in B. animalis IPLA R1,  although both microorganisms still remained 404 
alive for granting a daily intake in rats of about 108 cfu. It has been indicated that B. animalis 405 
species displays good tolerance to oxygen (oxidative stress), thus being able to keep higher 406 
counts during manufacture and cold storage of fermented products than other species 407 
(Gueimonde et al., 2004a; Jayamanne and Adams, 2009). The suspension of our strains in 408 
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10%-skimmed milk increased their survival to the chemically simulated GIT passage. In spite 409 
of this, strain E44 was considerably less tolerant to the harsh GIT conditions (acid, bile and 410 
digestive enzymes) than strain R1. Previous studies indicated that the response and adaptation 411 
of B. animalis and B. longum to different stresses differed between both species (Sánchez et 412 
al., 2008). It has been reported that B. animalis is more resistant to acidic conditions than B. 413 
longum (Masco et al., 2007) and in the same way we have recently demonstrated that strains 414 
of B. longum,  other than E44, were more sensitive to human gastric and duodenal juices than 415 
B. animalis strains (de los Reyes-Gavilán et al., 2010). Besides, B. animalis IPLA R1 is a 416 
bile-adapted strain obtained in our laboratory by exposure of the original sensitive strain to 417 
increasing concentrations of bile salts, this probably being another reason for the higher 418 
survival in the chemically simulated GIT of this strain with respect to B. longum IPLA E44, 419 
which is a natural isolate from human faeces (Salazar et al., 2008).  420 
Safety is one of the most important criteria for the selection of putative probiotic 421 
strains for human consumption. The absence of microbial deleterious metabolic activities, 422 
such as those enzymes involved in the transformation of pre-carcinogens into active 423 
carcinogens, as well as antibiotic resistance patterns, are recommended (FAO/WHO, 2006). 424 
Enzymatic activities such as β-glucosidase and N-acetyl-β-galactosaminidase related with 425 
harmful effects in the colon (Parodi, 1999) were detected at low levels in one, or both, of our 426 
strains whereas the pro-carcinogenic activivity β−glucuronidase was not present. In addition, 427 
E44 and R1 displayed high β-galactosidase activity levels, which have been related with 428 
alleviation of symptoms of lactose intolerance. MIC values for most antibiotics were in the 429 
range of that described in bifidobacteria (Delgado et al., 2005, 2008). Both microorganisms 430 
displayed resistance to aminoglycosides. The intrinsic resistance to aminoglycosides is a 431 
common feature in bifidobacteria due to the anaerobic nature of these microorganisms (Mättö 432 
et al. 2007) which lack cytochrome-mediated transport (Bryan and Kwan 1981). In addition, 433 
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B. animalis subsp. lactis IPLA R1 was resistant to tetracycline, whereas E44 was sensitive. It 434 
has been indicated that around 30% of human isolated bifidobacteria are resistant to 435 
tetracycline and that dominant species in human adults frequently harbour the tet(W) gene 436 
responsible for this resistance (Flórez et al., 2006). In our case, the tet(W) gene, as well as 437 
other genes encoding ribosomal protection proteins were absent in B. longum IPLA E44 but 438 
they were present in B. animalis IPLA R1. In this regard, a recent screening of 26 B. animalis 439 
strains from a variety of sources revealed the presence of tet(W) in all isolates (Gueimonde et 440 
al., 2010). A step forward to test the safety of orally delivered probiotic strains is in vivo tests 441 
using animal models (Huang et al., 2003; Lara-Villoslada et al., 2007; Maragkoudakis, 2009; 442 
Tsai et al., 2004; Zhou et al., 2000). The general parameters indicating the well-being status 443 
of the Wistar rats used in our study were not affected by the administration of bifidobacteria 444 
strains. In addition, bacterial translocation to the liver, spleen and mesenteric nodes induced 445 
by the oral administration of the bifidobacteria E44 and R1 strains was not detected, and 446 
microbial counts recovered from these organs were in the same range, or even in a lower 447 
range, than that reported in literature (Lara-Villoslada et al., 2007; Liong, 2008; 448 
Maragkoudakis, 2009). The histological examination of the gut tissues revealed no apparent 449 
morphological changes induced by our bifidobacteria. These results support the safety of the 450 
strain for oral consumption. 451 
Suspensions in 10%- skimmed milk of bifidobacteria were orally administered daily 452 
for 24 days to two groups of male Wistar rats and several parameters were analysed and 453 
compared against a placebo group not fed bifidobacteria. The qPCR counts of total 454 
bifidobacteria population in faeces resulted in significantly higher levels of this genus in the 455 
two groups fed either R1 or E44 strains with respect to the placebo group at the end of the 456 
treatment. Apart this, in the three groups of rats final levels of faecal bifidobacteria were of 457 
the same order as the initial ones and the increase of about 0.5 log units found at the 4th day 458 
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of intervention may be attributed to diet changes promoted by the administration of milk. 459 
Moreover, the oral intake of either B. animalis IPLA R1 or B. longum IPLA E44 strains led to 460 
higher levels of the genus Bifidobacterium and of the species B. animalis in caecum-content, 461 
without promoting noticeable variations in the total viable anaerobic population among the 462 
three groups of rats. In contrast, significantly higher levels of the species B. longum resulted 463 
from the intake of the strain B. longum IPLA E44 whereas the administration of B. animalis 464 
IPLA R1 had no any remarkable effect. It is worth mentioning also the maintenance of B. 465 
animalis levels in the caecum during treatment and the concomitant decrease of about 1 log 466 
unit of B. longum population in the same period. This suggests that diet modification of rats 467 
during our study by administration of skimmed milk to the three designed groups could have 468 
allowed the rearrangement of the intestinal bifidobacteria population, favouring the survival 469 
of B. animalis and impairing permanence of B. longum. In a similar way In this respect, 470 
Ouwehand and co-workers found in a previous work (2008) that the oral administration of B. 471 
animalis subsp. lactis Bb-12 to elderly subjects resulted in faecal increased levels of B. 472 
animalis, but no significant changes in the levels of other bifidobacteria were observed. Some 473 
previous studies have also demonstrated that feeding rats with probiotics, prebiotics or 474 
synbiotics promoted increases of bifidobacteria population at different locations in the rat GIT 475 
(Lesniewska et al., 2006; Montesi et al., 2005; Vasquez et al., 2009). Similar results have 476 
been also found in other rodent models (Kumar et al., 2008; Plant et al., 2003). Total 477 
bifidobacteria counts obtained in our study by using qPCR were in the same order of that 478 
reported for rat faecal samples by other authors (Delroisse et al., 2008). In this respect, 479 
Montesi and co-workers (2005) found that B. animalis is the most abundant species in Wistar 480 
rats whereas Vasquez and co-authors (2009) indicated that is Bifidobacterium pseudolongum. 481 
On the other hand, the PCR-DGGE analysis of microbial populations in caecum-content 482 
showed that rats fed B. animalis IPLA R1 presented a higher diversity of bands than the 483 
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placebo group, or the group of rats fed B. longum IPLA E44. These differences in the effect 484 
promoted by both microorganisms could be related to their different survival rates, different 485 
intrinsic characteristics of each strain, and/or to the influence of the administration of 486 
skimmed milk together with probiotics in the dynamics of the different bifidobacterial 487 
intestinal populations. In this way, other authors have noticed an increase in the number of 488 
PCR amplification products subsequent to probiotic / prebiotic treatments (Licht et al., 2006; 489 
Montesi et al., 2005; Sarmiento-Rubiano et al., 2007). In our work we have not been able to 490 
associate a bacterial fingerprint with the oral administration of a given bifidobacteria strain; 491 
this is probably due to the complexity of the rat microbiota which is unique for each 492 
individual, as has also been reported for the human microbiota (Favier et al., 2002; Vanhoutte 493 
et al., 2004). Amplification and sequencing of several bands of PCR-DGGE gels allowed us 494 
to identify microorganisms belonging to clostridial clusters XIVa, XI, and IV. Although 495 
lactobacilli have been identified in faecal samples they were not found in the caecum-content. 496 
No other bacterial groups, usually found in the gut microbiota of rats such as bacteroides or 497 
enterobacteria (Lesniewska et al., 2006; Licht et al., 2006; Montesi et al., 2005), were 498 
identified, which could be partly attributed to limitations of primers and experimental 499 
conditions used in the present work for PCR amplifications (Vanhoutte et al., 2004).  500 
SCFA are metabolites produced by the intestinal microbiota and they play an 501 
important role by maintaining a healthy colonic environment (Wong et al., 2006). The amount 502 
of total SCFA as well as acetate, propionate and butyrate increased during the treatment in our 503 
placebo and bifidobacteria-treated groups which could be due to the introduction of skimmed 504 
milk acting as prebiotic in the diet of rats. The total SCFA concentration in our placebo group 505 
was close to the range reported in literature for Wistar rats (Juskiewicz et al., 2007; 506 
Sarmiento-Rubiano et al., 2007). Notably, the total SCFA concentration was significantly 507 
lower in the caecum-content, and higher in the faecal samples of bifidobacteria-fed groups, 508 
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with respect to that of the placebo group. This suggests that the production of SCFA is 509 
probably being enhanced in parts of the colon beyond the caecum in rats fed bifidobacteria. 510 
Proportions of acetate and butyrate were of the same order in caecum-content samples, 511 
whereas in faeces the acetate was dominant over butyrate. This fact was attributed not only to 512 
higher absolute concentrations of acetate, but also to lower absolute concentrations of 513 
butyrate. The lower level of butyrate in faeces with respect to the caecum could be explained 514 
by a fast consumption of this SCFA by the epithelial intestinal cells of the distal intestine. The 515 
higher level of acetate in faeces suggests that the microbiota located between the caecum and 516 
distal intestine was actively producing this metabolite. This fact agrees with the enhancement 517 
of SCFA production found by us in distal parts of the intestine when bifidobacteria were 518 
orally administered.  519 
In conclusion, in vitro and in vivo studies corroborated the safety of strains B. animalis 520 
IPLA R1 and B. longum IPLA E44 and the better survival of R1 than E44 to refrigerated 521 
storage and to the GIT transit. The continuous administration of both strains to Wistar rats 522 
promoted significant changes in the population of bifidobacteria and in the SCFA 523 
concentration of faeces and caecum-content without affecting total anaerobic counts and 524 
proportions of different major SCFA, thus contributing to modulate the intestinal microbiota 525 
of rats.   526 
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FIGURE LEGENDS  689 
Figure 1: Survival to the chemically simulated GIT of B. animalis subsp. lactis IPLA R1 and 690 
B. longum subsp. longum IPLA E44. Counts (log cfu/mL) were obtained at each sampling 691 
point (a) and the percentage of survival by using fluorescence probes (Live/Dead® BacLigth, 692 
Invitrogen) was measured at the end of the GIT transit (b). Simulated GIT transit steps, GJ: 693 
gastric juice, DJ: duodenal juice and IJ: intestinal juice. GJ pH 2.0 (●), GJ pH 3.0 (□) and GJ 694 
pH 2.0 + 10%-skimmed milk (▲). The coefficient of variation (100* SD/mean) of these data 695 
ranged between 1.1 – 2.3% (a) and 4.3 – 17.7% (b). At the end of the GIT challenge, the 696 
symbols/bars that do not share a common letter are significantly (p<0.05) different according 697 
to the mean comparison test LSD.  698 
 699 
Figure 2: Photomicrographs of small and large intestine sections stained with haematoxylin-700 
eosin in control rats at 0 days (a), rats fed with placebo after 24 days (b), rats fed with 701 
bacterial suspensions in milk (109 cfu/day) of B. animalis subsp. lactis IPLA R1 (B1 group) 702 
after 24 days (c), and of B. longum subsp. longum IPLA E44 (B2 group) after 24 days (d).  703 
Crypts are indicated by filled arrows and villi are indicated by dashed arrows.  704 
 705 
Figure 3: Quantitative PCR counts (log nº cells /gram) of the Bifidobacterium genus in faecal 706 
samples at different sampling points (a) and of genus Bifidobacterium and species B. animalis 707 
and B. longum (detection limit 4.0, 4.0 and 4.6 log cfu/mL, respectively) in caecum-content 708 
samples at 0 and after 24 days of treatment (b) in three groups of rats fed placebo (skimmed 709 
milk, black symbol) or bacterial suspensions in milk (109 cfu/day) of B. animalis subsp. lactis 710 
IPLA R1 (group B1, grey symbol) and B. longum subsp. longum IPLA E44 (group B2, white 711 
symbol). The coefficient of variation (100* SD/mean) of these data ranged between 1.9 and 712 
 31
3.7% in graphic (a). For each sampling point, results that do not share a common letter are 713 
significantly (p<0.05) different according to the mean comparison test LSD.  714 
 715 
Figure 4: PCR-DGGE profiles (a) of caecum-content samples obtained after 24 days from 716 
four rats (R1, R2, R3 and R4) of each group tested: rats fed with placebo (P), with bacterial 717 
suspensions in milk (109 cfu/day) of B. animalis subsp. lactis IPLA R1 (B1) and B. longum 718 
subsp. longum IPLA E44 (B2). Numbers inside the gels refer to sequenced DNA bands, 719 
whose tentative identification is indicated in Table 1. “Box and whiskers” representation of 720 
the PCR-DGGE diversity (number of bands) analysed in eight rats per treatment group (b); 721 
boxes that do not share a common letter are significantly different (p<0.001) accordingly to 722 
the non-parametric Mann-Whitney test.  723 
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